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Abstract 
Review on del(13q) in chronic lymphocytic 
leukemia, with data on clinics, and the genes 
involved. 
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Clinics and pathology 
Disease 
Chronic lymphocytic leukemia (CLL) is the most 
common leukemia in adults, with a highly variable 
clinical course, ranging from very indolent cases to 
a very aggressive and rapidly progressing disease 
(Puiggros et al., 2014). Although is characterized by 
a relatively stable genome, acquired genetic 
aberrations have an important role in CLL prognosis. 
The most frequent chromosomal abnormalities are 
partial losses of one affected chromosome (del(6q), 
del(11q), del(13q) or del(17p)) and gains of entire 
chromosomes ( trisomy 12). (Baliakas et al., 2014). 
Etiology 
The pathogenic role of del(13q) in CLL has been 
related to lack of B-cell proliferation control 
allegedly determined by deletion of the DLEU2/ 
MIR15A/ MIR16-1 locus, which is known to contain 
negative regulators of the expression of the BCL2 
gene (Cimmino et al., 2005; Klein et al., 2010).  
The RB1 gene is involved in the regulation of cell 
cycle progression and genomic stability.  
Biallelic 13q deletions are characteristically small 
and do not involve RB1 deletions, nevertheless their 
clinical impact has been controversial. Thus, the 
potential effect could be masked by the size of the 
deleted region or the inactivation of the remaining 
allele by other mechanism.  
Related to the size of abnormal clone (detected by 
FISH), patients with a higher percentage of altered 
nuclei (cut-off point ranged from 65-90%) have a 
bad prognosis (van Dyke et al., 2010). 
Those patients with large 13q losses showed 
downregulation of ten genes including TPT1 
(TCTP), which in involved in prosurvival and 
growth signaling through inhibition of BAX-induced 
apoptosis and overexpression of 53 genes.  
Other genetic abnormalities: GPS2 (AMF), GPI, 
BSG, LGALS1, PAK2, PARVBand VIM participate 
in cell motility, adhesion, and regulation of cell 
proliferation, tumor cell migration, metastasis, 
angiogenesis and apoptosis (Rodriguez et al., 2012). 
Epidemiology 
Del(13q) involving the band q14, found in more than 
50% of CLL patients, is the most common 
cytogenetic abnormality detected by FISH, and has 
been associated with good prognosis.  
Del(13q) as the sole aberration occurs in the 
hemizygous state in approximately 75-80% of cases 
and in the homozygous state in the remaining 20-
25% (Migliazza et al., 2001). 
Cytology 
The CLL-cells characteristics are the same, 
independently of the chromosomal abnormalities. 
The peripheral blood smear of patients with CLL  
demonstrates a lymphocytosis. The leukemic cells 
are typically small, mature appearing lymphocytes 
with a dense nucleus, partially aggregated (clumped) 
chromatin, and without discernible nucleoli. There is 
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a narrow border of clear to slightly basophilic 
cytoplasm. 
Cytogenetics 
Two anatomical landmarks have been proposed for 
the characterization of 13q deletion in CLL:  
I- The minimal deleted region (MDR), which 
comprised the DLEU2 gene, the MIR15A/MIR16-1 
cluster, and the first exon of the DLEU1 gene. (Liu 
et al., 1997; Lagos-Quintana et al., 2002)  
II-The RB1 gene, localized at chromosomal band 
13q14.1-q14.2 that can be considered, when found 
deleted, as the marker of 13q deletion with larger 
chromosome losses (Ouillette et al., 2008; Parker et 
al., 2011).  
Other genes located in 13q, such as DLEU7 or 
TRIM13 could cooperate in the tumoral suppressor 
activity. 
Treatment 
Del(13q) patients, responds better to alkylating 
agents (fludarabine and chorambucil) and potentially 
can have a long term PFS with these therapies unlike 
del(17p) patients. 
Prognosis 
Del(13q) in any form has a better prognosis than 
del(17p) (3-8% of CLL at diagnosis and up 30% in 
refractory CLL cases) or del(11q) (detected in 5-
20% of CLL patients) (Döhner et al., 2000). 
It has been extensively demonstrated that large 13q 
losses involving RB1 gene are related to shorter time 
to first treatment (TTFT) and overall survival (OS) 
than those small deletions encompassing only 
MIR15A/MIR16-1.   
Although CLL with 13q deletion as the sole 
cytogenetic abnormality usually have good 
prognosis, more aggressive clinical courses are 
documented for del(13q)-only CLL carrying higher 
percentage of 13q-deleted nuclei. Many published 
studies had demonstrated the prognosis 
heterogeneity that occurs in patients with this 
chromosomal abnormality, which can be revealed by 
FISH analysis of both deletion load and deletion 
size, suggesting the existence of additional factors 
(deletions of different sizes) in defining del(13q)-
only CLL prognosis (Dal Bo et al., 2011). 
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